Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | PPIA | P62937 | 2/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1L1 | Q9UHC9 | 5/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16150156 | 0.88 | MAPT (0.36) | FASNMAPTRXFP1PPIAHTT | |
| SCHEMBL21497425 | 0.84 | FASN (0.36) | FASNMAPTRXFP1CNR2NAMPT | |
| SCHEMBL16150106 | 0.83 | KMT2A (0.52) | MAPTRXFP1CNR2KDM4EALDH1A1 | |
| SCHEMBL16150679 | 0.80 | FASN (0.64) | FASNMAPTRXFP1KDM4EALDH1A1 | |
| SCHEMBL17404611 | 0.79 | FASN (0.49) | FASNMAPTRXFP1KDM4EALDH1A1 | |
| SCHEMBL16151197 | 0.76 | MAPT (0.49) | FASNMAPTRXFP1KDM4EALDH1A1 | |
| SCHEMBL16149873 | 0.75 | RXFP1 (0.40) | FASNMAPTRXFP1KDM4EALDH1A1 | |
| SCHEMBL17404603 | 0.73 | SIGMAR1 (0.54) | MAPTRXFP1CNR2KDM4EALDH1A1 | |
| SCHEMBL21555271 | 0.72 | FASN (0.45) | FASNMAPTRXFP1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL16149706 | 0.72 | SIGMAR1 (0.52) | MAPTRXFP1CNR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| EP-2968316-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885MAPT 3475/4885RXFP1 4584/4885 |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885MAPT 3475/4885RXFP1 4584/4885 |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | FASN 1/4885MAPT 3486/4885RXFP1 4659/4885 |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | FASN 1/4885MAPT 3053/4885RXFP1 4617/4885 |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885MAPT 3475/4885RXFP1 4584/4885 |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885MAPT 3475/4885RXFP1 4584/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885MAPT 3475/4885RXFP1 4584/4885 |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | FASN 1/4885MAPT 3053/4885RXFP1 4617/4885 |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | FASN 1/4885MAPT 3053/4885RXFP1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.